Detalhe da pesquisa
1.
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
BJU Int
; 114(6b): E25-E31, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24298897
2.
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
BJU Int
; 110(11 Pt B): E461-8, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22520631
3.
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Urol Oncol
; 31(8): 1457-63, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22552048
4.
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Clin Genitourin Cancer
; 10(4): 239-45, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23000202
5.
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Eur Urol
; 61(2): 363-9, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21715086
6.
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
J Thorac Oncol
; 6(4): 781-5, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21289522